See the workflow before you discuss the engagement.

The public pharma demo is a synthetic product-direction experience. It shows source organization, CTD structure, drafting, and review states; it does not prove a production deployment, client result, validation, security, privacy, or compliance.

What to inspect.

  1. Source structureHow preloaded synthetic material is organized before drafting.
  2. Dossier navigationHow CTD sections, status, and source context can remain visible.
  3. Review statesWhere exceptions, edits, named review, and final decisions would belong.
  4. Production boundaryWhich architecture, data, validation, integration, and operating questions remain to be scoped.
Use only the preloaded synthetic material. Do not upload client, product, patient, safety, credential, or controlled information.

Four fields. Then the demo opens.

Tell us who is inspecting the workflow and what you need to see. Do not include product, patient, safety, credential, or controlled information.

By continuing, you ask Durability Labs to use these details to understand demo interest and respond about this need. This does not enroll you in marketing. See the privacy notice.

Demo direction is not a universal production inclusion.

Open-source components, on-premises or hybrid deployment, orchestration, SSO, audit history, and named system integrations require engagement-specific design, authorization, testing, and operating ownership.

Models and infrastructure

Assess licensing, hardware, updates, access, support, data flow, and acceptance evidence.

Integrations and records

Assess authorized APIs, identity, mapping, failures, audit requirements, and client acceptance.

Regulated use

Intended use, complete-system evidence, procedures, qualified roles, and client approval determine fitness.

After the demo, bring the workflow—not the files.

A fit call with Saad starts with the bottleneck, source types, decision owner, timing, and deployment constraints at a non-confidential level.